首页 > 最新文献

Precision Clinical Medicine最新文献

英文 中文
Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas 染色体9p21缺失与胰腺腺鳞癌预后不良相关
4区 医学 Q1 Medicine Pub Date : 2023-11-07 DOI: 10.1093/pcmedi/pbad030
Yina Jiang, YinYing Wu, Liwen Zhang, Yan Wang, Guiping Xu, Yuan Deng, Liang Han, Enxiao Li, Qingyong Ma, Mian Xu, Zheng Wu, Zheng Wang
Abstract Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. Forty-eight ASCP specimens and 98 pancreatic ductal adenocarcinoma (PDAC) tumours pecimens were sequenced to explore the genomic landscape and prognostic biomarkers. The homozygous deletion of the 9p21.3 region (including CDKN2A, CDKN2B, and MTAP) (9p21 loss) occurred in both ASCP and PDAC, and a higher frequency of 9p21 loss was observed in ASCP (12.5% vs. 2.0%, p = 0.022). Notably, 9p21 loss was significantly associated with poor disease-free survival (DFS) in ASCP patients (mDFS = 4.17 vs. 7.33 months, HR = 3.70, p = 0.009). The most common gene alterations in patients with ASCP were KRAS (96%), TP53 (81%), CDKN2A (42%), SMAD4 (21%), CDKN2B (13%), and FAT3 (13%). The mutation rates of ACVR2A (6.25% vs. 0), FANCA (6.25% vs. 0), RBM10 (6.25% vs. 0), and SPTA1 (8.33% vs. 1.02%) were significantly higher in ASCP than in PDAC. In conclusion, we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP, which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.
摘要胰腺腺鳞癌(Adenosquamous carcinoma of pancreatic, ASCP)是一种少见的胰腺组织学亚型,预后差,转移率高。然而,对其基因组景观和预后生物标志物知之甚少。对48例ASCP标本和98例胰腺导管腺癌(PDAC)肿瘤标本进行测序,以探索基因组景观和预后生物标志物。9p21.3区域(包括CDKN2A、CDKN2B和MTAP)的纯合缺失(9p21缺失)在ASCP和PDAC中均有发生,且ASCP中9p21缺失的频率更高(12.5% vs. 2.0%, p = 0.022)。值得注意的是,9p21缺失与ASCP患者较差的无病生存期(DFS)显著相关(mDFS = 4.17 vs. 7.33个月,HR = 3.70, p = 0.009)。ASCP患者中最常见的基因改变是KRAS(96%)、TP53(81%)、CDKN2A(42%)、SMAD4(21%)、CDKN2B(13%)和FAT3(13%)。ACVR2A (6.25% vs. 0)、FANCA (6.25% vs. 0)、RBM10 (6.25% vs. 0)和SPTA1 (8.33% vs. 1.02%)在ASCP患者中的突变率显著高于PDAC患者。总之,我们全面描述了迄今为止最大的ASCP患者队列的基因组景观,并强调9p21缺失可能是ASCP的一个有希望的预后生物标志物,为ASCP的预后预测和新的治疗策略提供了分子基础。
{"title":"Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas","authors":"Yina Jiang, YinYing Wu, Liwen Zhang, Yan Wang, Guiping Xu, Yuan Deng, Liang Han, Enxiao Li, Qingyong Ma, Mian Xu, Zheng Wu, Zheng Wang","doi":"10.1093/pcmedi/pbad030","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad030","url":null,"abstract":"Abstract Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. Forty-eight ASCP specimens and 98 pancreatic ductal adenocarcinoma (PDAC) tumours pecimens were sequenced to explore the genomic landscape and prognostic biomarkers. The homozygous deletion of the 9p21.3 region (including CDKN2A, CDKN2B, and MTAP) (9p21 loss) occurred in both ASCP and PDAC, and a higher frequency of 9p21 loss was observed in ASCP (12.5% vs. 2.0%, p = 0.022). Notably, 9p21 loss was significantly associated with poor disease-free survival (DFS) in ASCP patients (mDFS = 4.17 vs. 7.33 months, HR = 3.70, p = 0.009). The most common gene alterations in patients with ASCP were KRAS (96%), TP53 (81%), CDKN2A (42%), SMAD4 (21%), CDKN2B (13%), and FAT3 (13%). The mutation rates of ACVR2A (6.25% vs. 0), FANCA (6.25% vs. 0), RBM10 (6.25% vs. 0), and SPTA1 (8.33% vs. 1.02%) were significantly higher in ASCP than in PDAC. In conclusion, we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP, which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135541640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A pairwise radiomics algorithm - lesion pair relation estimation (PRE) model for distinguishing multiple primary lung cancer (MPLC) from intrapulmonary metastasis (IPM) 两两放射组学算法-病变对关系估计(PRE)模型鉴别多发性原发性肺癌(MPLC)与肺内转移(IPM)
4区 医学 Q1 Medicine Pub Date : 2023-10-30 DOI: 10.1093/pcmedi/pbad029
Ting-Fei Chen, Lei Yang, Hai-Bin Chen, Zhi-Guo Zhou, Zhen-Tian Wu, Hong-He Luo, Qiong Li, Ying Zhu
Abstract Background Distinguishing multiple primary lung cancer (MPLC) from intrapulmonary metastasis (IPM) is critical for their disparate treatment strategy and prognosis. This study aimed to establish a non-invasive model to make the differentiation pre-operatively. Methods We retrospectively studied 168 patients with multiple lung cancers (307 pairs of lesions) including 118 cases for modeling and internal validation, and 50 cases for independent external validation. Radiomic features on computed tomography (CT) were extracted to calculate the absolute deviation of paired lesions. Features were then selected by correlation coefficients and random forest classifier five-fold cross-validation, based on which the lesion pair relation estimation (PRE) model was developed. A major voting strategy was used to decide diagnosis for cases with multiple pairs of lesions. Cases from another institute were included as the external validation set for the PRE model to compete with two experienced clinicians. Results Seven radiomic features were selected for the PRE model construction. With major voting strategy, the mean area under receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity of the training vs. internal validation vs. external validation cohort to distinguish MPLC were 0.983 vs. 0.844 vs. 0.793, 0.942 vs. 0.846 vs. 0.760, 0.905 vs. 0.728 vs. 0.727, and 0.962 vs. 0.910 vs. 0.769, respectively. AUCs of the two clinicians were 0.619 and 0.580. Conclusions The CT radiomic feature-based lesion PRE model is potentially an accurate diagnostic tool for the differentiation of MPLC and IPM, which could help with clinical decision making.
背景区分多发原发性肺癌(MPLC)和肺内转移(IPM)对于其不同的治疗策略和预后至关重要。本研究旨在建立无创模型进行术前鉴别。方法回顾性研究168例多发性肺癌患者(307对病变),其中118例进行建模和内部验证,50例进行独立外部验证。提取计算机断层扫描(CT)上的放射学特征来计算成对病变的绝对偏差。然后通过相关系数和随机森林分类器五重交叉验证选择特征,在此基础上建立病变对关系估计(PRE)模型。一个主要的投票策略被用来决定多对病变病例的诊断。来自另一个研究所的病例被纳入PRE模型的外部验证集,与两位经验丰富的临床医生竞争。结果选取7个放射学特征进行PRE模型构建。在主要投票策略下,训练组、内部验证组和外部验证组区分MPLC的平均受试者工作特征曲线下面积(AUC)、准确度、灵敏度和特异性分别为0.983、0.844、0.793、0.942、0.846、0.760、0.905、0.728、0.727、0.962、0.910、0.769。两名临床医生的auc分别为0.619和0.580。结论基于CT放射学特征的病变PRE模型可作为MPLC与IPM鉴别的准确诊断工具,有助于临床决策。
{"title":"A pairwise radiomics algorithm - lesion pair relation estimation (PRE) model for distinguishing multiple primary lung cancer (MPLC) from intrapulmonary metastasis (IPM)","authors":"Ting-Fei Chen, Lei Yang, Hai-Bin Chen, Zhi-Guo Zhou, Zhen-Tian Wu, Hong-He Luo, Qiong Li, Ying Zhu","doi":"10.1093/pcmedi/pbad029","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad029","url":null,"abstract":"Abstract Background Distinguishing multiple primary lung cancer (MPLC) from intrapulmonary metastasis (IPM) is critical for their disparate treatment strategy and prognosis. This study aimed to establish a non-invasive model to make the differentiation pre-operatively. Methods We retrospectively studied 168 patients with multiple lung cancers (307 pairs of lesions) including 118 cases for modeling and internal validation, and 50 cases for independent external validation. Radiomic features on computed tomography (CT) were extracted to calculate the absolute deviation of paired lesions. Features were then selected by correlation coefficients and random forest classifier five-fold cross-validation, based on which the lesion pair relation estimation (PRE) model was developed. A major voting strategy was used to decide diagnosis for cases with multiple pairs of lesions. Cases from another institute were included as the external validation set for the PRE model to compete with two experienced clinicians. Results Seven radiomic features were selected for the PRE model construction. With major voting strategy, the mean area under receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity of the training vs. internal validation vs. external validation cohort to distinguish MPLC were 0.983 vs. 0.844 vs. 0.793, 0.942 vs. 0.846 vs. 0.760, 0.905 vs. 0.728 vs. 0.727, and 0.962 vs. 0.910 vs. 0.769, respectively. AUCs of the two clinicians were 0.619 and 0.580. Conclusions The CT radiomic feature-based lesion PRE model is potentially an accurate diagnostic tool for the differentiation of MPLC and IPM, which could help with clinical decision making.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136069325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the gut microbiota's influence on psoriasis and psoriatic arthritis risk: a Mendelian randomization analysis. 研究肠道微生物群对银屑病和银屑病关节炎风险的影响:孟德尔随机分析。
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-09-15 eCollection Date: 2023-09-01 DOI: 10.1093/pcmedi/pbad023
Nianzhou Yu, Jiayi Wang, Yuancheng Liu, Yeye Guo

Background: Numerous investigations have revealed the interplay between gut microbiota (GM) and psoriasis (Ps) and psoriatic arthritis (PsA). However, the causal relationship between them remains unknown.

Methods: We curated a collection of genetic variants (P < 1 × 10-5) associated with GM (n = 18 340) derived from the MiBioGen study. To explore the intricate relationship between GM and Ps as well as PsA, we harnessed the comprehensive resources of the FinnGen database, encompassing a vast cohort of individuals, including 4510 Ps cases and 212 242 controls and 1637 PsA cases and 212 242 controls. Mendelian randomization (MR) was used, including an inverse variance weighting method, followed by a sensitivity analysis to verify the robustness of the results.

Results: For Ps, some bacterial taxa, including Lactococcus, Ruminiclostridium 5, and Eubacterium fissicatena, were identified as risk factors; but Odoribacter demonstrated a protective effect against Ps. In the case of PsA, Lactococcus, Verrucomicrobiales, Akkermansia, Coprococcus 1, and Verrucomicrobiaceae were identified as risk factors; Odoribacter and Rikenellaceae exhibited a protective effect against the development of PsA.

Conclusion: Our study establishes a causal link between the GM and Ps and PsA. These findings provide insights into the underlying mechanisms and suggest potential therapeutic targets.

背景:大量研究揭示了肠道微生物群(GM)与银屑病(Ps)和银屑病关节炎(PsA)之间的相互作用。然而,它们之间的因果关系尚不清楚。方法:我们收集了来自MiBioGen研究的与GM相关的遗传变异(P -5) (n = 18 340)。为了探索GM、Ps和PsA之间的复杂关系,我们利用了FinnGen数据库的综合资源,其中包括大量个体,包括4510例Ps病例和212 242例对照,以及1637例PsA病例和212 242例对照。采用孟德尔随机化(MR),包括方差逆加权法,然后进行敏感性分析以验证结果的稳健性。结果:乳球菌、5型反刍芽胞杆菌和裂裂真杆菌是Ps的危险因素;在PsA病例中,乳球菌(Lactococcus)、Verrucomicrobiales、Akkermansia、Coprococcus 1和Verrucomicrobiaceae被确定为危险因素;气味杆菌和里氏菌科对PsA的发生具有保护作用。结论:我们的研究建立了GM与Ps和PsA之间的因果关系。这些发现提供了对潜在机制的见解,并提出了潜在的治疗靶点。
{"title":"Investigating the gut microbiota's influence on psoriasis and psoriatic arthritis risk: a Mendelian randomization analysis.","authors":"Nianzhou Yu, Jiayi Wang, Yuancheng Liu, Yeye Guo","doi":"10.1093/pcmedi/pbad023","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad023","url":null,"abstract":"<p><strong>Background: </strong>Numerous investigations have revealed the interplay between gut microbiota (GM) and psoriasis (Ps) and psoriatic arthritis (PsA). However, the causal relationship between them remains unknown.</p><p><strong>Methods: </strong>We curated a collection of genetic variants (<i>P</i> < 1 × 10<sup>-5</sup>) associated with GM (<i>n</i> = 18 340) derived from the MiBioGen study. To explore the intricate relationship between GM and Ps as well as PsA, we harnessed the comprehensive resources of the FinnGen database, encompassing a vast cohort of individuals, including 4510 Ps cases and 212 242 controls and 1637 PsA cases and 212 242 controls. Mendelian randomization (MR) was used, including an inverse variance weighting method, followed by a sensitivity analysis to verify the robustness of the results.</p><p><strong>Results: </strong>For Ps, some bacterial taxa, including <i>Lactococcus, Ruminiclostridium 5</i>, and <i>Eubacterium fissicatena</i>, were identified as risk factors; but <i>Odoribacter</i> demonstrated a protective effect against Ps. In the case of PsA, <i>Lactococcus, Verrucomicrobiales, Akkermansia, Coprococcus 1</i>, and <i>Verrucomicrobiaceae</i> were identified as risk factors; <i>Odoribacter</i> and <i>Rikenellaceae</i> exhibited a protective effect against the development of PsA.</p><p><strong>Conclusion: </strong>Our study establishes a causal link between the GM and Ps and PsA. These findings provide insights into the underlying mechanisms and suggest potential therapeutic targets.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis. 粪乳铁蛋白预测溃疡性结肠炎预后的轨迹。
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-09-05 eCollection Date: 2023-09-01 DOI: 10.1093/pcmedi/pbad022
Rirong Chen, Li Li, Yizhe Tie, Minhu Chen, Shenghong Zhang

Objectives: To investigate the characteristics and prognostic value of fecal lactoferrin trajectories in ulcerative colitis (UC).

Methods: This study used data from the UNIFI trial (ClinicalTrials.gov, NCT02407236) and included patients who received ustekinumab during induction for trajectory modeling (n = 637). Patients who received ustekinumab during maintenance therapy were used for 1-year outcome analyses (n = 403). The levels of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were measured at weeks 0, 2, 4, and 8. The trajectories of these biomarkers were developed using a latent class growth mixed model.

Results: The trajectories of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were distinct, but all were associated with prior exposure to anti-tumor necrosis factor agents and vedolizumab. Furthermore, the fecal lactoferrin trajectory was the most valuable predictor of endoscopic, clinical, and histological remission. Compared to the high/moderate-rapid decrease trajectory group, the moderate-slow decrease, high-slow decrease, and high-stable groups had adjusted odds ratios (95% confidence interval) of 0.38 (0.18, 0.78; = 0.010), 0.47 (0.23, 0.93; = 0.032), and 0.33 (0.17, 0.63; P = 0.001), respectively, of 1-year endoscopic remission. Patients with high/moderate-rapid decrease trajectories also had the highest likelihood of achieving clinical and histological remission. Finally, we developed a patient-stratification scheme based on fecal lactoferrin trajectories and concentrations. Patients with good, moderate, and poor prognoses in the scheme had a distinct probability of achieving 1-year endoscopic remission (52.7%, 30.9%, and 12.8%, respectively).

Conclusions: The trajectory of fecal lactoferrin is a valuable prognostic factor for 1-year remission in UC.

目的:探讨溃疡性结肠炎(UC)患者粪便乳铁蛋白轨迹的特点及预后价值。方法:本研究使用来自UNIFI试验(ClinicalTrials.gov, NCT02407236)的数据,包括在诱导期间接受ustekinumab的患者进行轨迹建模(n = 637)。在维持治疗期间接受ustekinumab治疗的患者用于1年结局分析(n = 403)。在第0、2、4和8周测定粪便乳铁蛋白、粪便钙保护蛋白和血清c反应蛋白的水平。使用潜在类生长混合模型开发了这些生物标志物的轨迹。结果:粪便乳铁蛋白、粪便钙保护蛋白和血清c反应蛋白的轨迹是不同的,但都与先前暴露于抗肿瘤坏死因子药物和维多单抗有关。此外,粪便乳铁蛋白轨迹是内镜、临床和组织学缓解的最有价值的预测指标。与高/中速下降轨迹组相比,中慢下降、高慢下降和高稳定组的校正优势比(95%可信区间)为0.38 (0.18,0.78;P = 0.010), 0.47 (0.23, 0.93;P = 0.032), 0.33 (0.17, 0.63;P = 0.001),分别为1年的内镜缓解。具有高/中速下降轨迹的患者也有最高的可能性实现临床和组织学缓解。最后,我们根据粪便乳铁蛋白轨迹和浓度制定了患者分层方案。在该方案中,预后良好、中等和较差的患者实现1年内镜缓解的概率明显(分别为52.7%、30.9%和12.8%)。结论:粪乳铁蛋白的轨迹是UC患者1年缓解的一个有价值的预后因素。
{"title":"Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis.","authors":"Rirong Chen, Li Li, Yizhe Tie, Minhu Chen, Shenghong Zhang","doi":"10.1093/pcmedi/pbad022","DOIUrl":"10.1093/pcmedi/pbad022","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the characteristics and prognostic value of fecal lactoferrin trajectories in ulcerative colitis (UC).</p><p><strong>Methods: </strong>This study used data from the UNIFI trial (ClinicalTrials.gov, NCT02407236) and included patients who received ustekinumab during induction for trajectory modeling (<i>n</i> = 637). Patients who received ustekinumab during maintenance therapy were used for 1-year outcome analyses (<i>n</i> = 403). The levels of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were measured at weeks 0, 2, 4, and 8. The trajectories of these biomarkers were developed using a latent class growth mixed model.</p><p><strong>Results: </strong>The trajectories of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were distinct, but all were associated with prior exposure to anti-tumor necrosis factor agents and vedolizumab. Furthermore, the fecal lactoferrin trajectory was the most valuable predictor of endoscopic, clinical, and histological remission. Compared to the high/moderate-rapid decrease trajectory group, the moderate-slow decrease, high-slow decrease, and high-stable groups had adjusted odds ratios (95% confidence interval) of 0.38 (0.18, 0.78; <i>P </i>= 0.010), 0.47 (0.23, 0.93; <i>P </i>= 0.032), and 0.33 (0.17, 0.63; <i>P</i> = 0.001), respectively, of 1-year endoscopic remission. Patients with high/moderate-rapid decrease trajectories also had the highest likelihood of achieving clinical and histological remission. Finally, we developed a patient-stratification scheme based on fecal lactoferrin trajectories and concentrations. Patients with good, moderate, and poor prognoses in the scheme had a distinct probability of achieving 1-year endoscopic remission (52.7%, 30.9%, and 12.8%, respectively).</p><p><strong>Conclusions: </strong>The trajectory of fecal lactoferrin is a valuable prognostic factor for 1-year remission in UC.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75218419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of apolipoprotein A1 on tumor immune microenvironment, clinical prognosis and genomic landscape in hepatocellular carcinoma. 载脂蛋白A1对肝细胞癌肿瘤免疫微环境、临床预后和基因组景观的影响
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-09-02 eCollection Date: 2023-09-01 DOI: 10.1093/pcmedi/pbad021
Ying Wang, Shipeng Chen, Xiao Xiao, Fan Yang, Jinhan Wang, Hui Zong, Yuzhen Gao, Chenjun Huang, Xuewen Xu, Meng Fang, Xiaoyan Zhang, Chunfang Gao

Background: Current knowledge on apolipoprotein A1 (APOA1) in hepatocellular carcinoma (HCC) is fragmented and even contradictory. Multi-dimensional analyses are required to comprehensively elucidate its value and underlying mechanism.

Methods: We collected 49 RNA-seq datasets, 40 cell line types data and 70 scRNA pan-cancer datasets public available, including 17 HCC datasets (1754 tumor samples), and enrolled 73 pairs of HCC tissue and 516 blood samples independently from our clinics. APOA1 impacting on the HCC tumor microenvironment (TME) was analyzed using intensive data mining. Methylation sequencing, flow cytometry, quantitative PCR, western blot, immunohistochemistry and clinical chemistry assays were conducted for wet experimental investigation.

Results: The APOA1 ontology fingerprint indicated that it played various crucial biological roles in HCC, primarily involved in cholesterol efflux. Consistent findings at histology, serology, and clinical follow-up revealed that high APOA1 was a good prognosis indicator of HCC. Hypermethylation in the APOA1 promoter region was found in clinical samples which is in accordance with the reduction of APOA1 in HCC. The cell cycle, DNA replication, mismatch repair pathways, and tumor cell proliferation were less observed in the HCC APOA1high subgroup. The favorable immunoregulatory abilities of APOA1 showed interesting findings: a positive correlation between APOA1 and anti-tumor immune cells (NK, CD8+ T cells) and a negative association with immune cells exerting immunosuppressive effects, including M2 macrophages.

Conclusion: This is an integrative multidimensional exploration of APOA1 using bioinformatics and experiments. Both the prognostic value and anti-tumor effects based on APOA1 panoramic exploration in the HCC TME demonstrate a new potential clinical target for HCC assessment and intervention in the future.

背景:目前关于载脂蛋白A1 (APOA1)在肝细胞癌(HCC)中的作用的认识是碎片化的,甚至是相互矛盾的。要全面阐明其价值和作用机制,需要多维度分析。方法:我们收集了49个RNA-seq数据集,40个细胞系类型数据集和70个scRNA泛癌症数据集,包括17个HCC数据集(1754个肿瘤样本),并独立从我们的诊所收集了73对HCC组织和516个血液样本。APOA1对HCC肿瘤微环境(TME)的影响采用密集的数据挖掘分析。采用甲基化测序、流式细胞术、定量PCR、western blot、免疫组织化学、临床化学等方法进行湿法实验研究。结果:APOA1本体论指纹图谱显示其在HCC中发挥多种重要的生物学作用,主要参与胆固醇外排。组织学、血清学和临床随访的一致结果表明,高APOA1是HCC的良好预后指标。在临床样本中发现APOA1启动子区域的高甲基化,这与HCC中APOA1的减少一致。细胞周期、DNA复制、错配修复途径和肿瘤细胞增殖在HCC apoa1高亚组中较少观察到。APOA1良好的免疫调节能力显示出有趣的发现:APOA1与抗肿瘤免疫细胞(NK、CD8+ T细胞)呈正相关,与具有免疫抑制作用的免疫细胞(包括M2巨噬细胞)负相关。结论:利用生物信息学和实验手段对APOA1进行了多维度的综合探索。基于APOA1全景探查在HCC TME中的预后价值和抗肿瘤作用,为未来HCC评估和干预提供了新的潜在临床靶点。
{"title":"Impact of apolipoprotein A1 on tumor immune microenvironment, clinical prognosis and genomic landscape in hepatocellular carcinoma.","authors":"Ying Wang, Shipeng Chen, Xiao Xiao, Fan Yang, Jinhan Wang, Hui Zong, Yuzhen Gao, Chenjun Huang, Xuewen Xu, Meng Fang, Xiaoyan Zhang, Chunfang Gao","doi":"10.1093/pcmedi/pbad021","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad021","url":null,"abstract":"<p><strong>Background: </strong>Current knowledge on apolipoprotein A1 (APOA1) in hepatocellular carcinoma (HCC) is fragmented and even contradictory. Multi-dimensional analyses are required to comprehensively elucidate its value and underlying mechanism.</p><p><strong>Methods: </strong>We collected 49 RNA-seq datasets, 40 cell line types data and 70 scRNA pan-cancer datasets public available, including 17 HCC datasets (1754 tumor samples), and enrolled 73 pairs of HCC tissue and 516 blood samples independently from our clinics. APOA1 impacting on the HCC tumor microenvironment (TME) was analyzed using intensive data mining. Methylation sequencing, flow cytometry, quantitative PCR, western blot, immunohistochemistry and clinical chemistry assays were conducted for wet experimental investigation.</p><p><strong>Results: </strong>The APOA1 ontology fingerprint indicated that it played various crucial biological roles in HCC, primarily involved in cholesterol efflux. Consistent findings at histology, serology, and clinical follow-up revealed that high APOA1 was a good prognosis indicator of HCC. Hypermethylation in the APOA1 promoter region was found in clinical samples which is in accordance with the reduction of APOA1 in HCC. The cell cycle, DNA replication, mismatch repair pathways, and tumor cell proliferation were less observed in the HCC APOA1<sup>high</sup> subgroup. The favorable immunoregulatory abilities of APOA1 showed interesting findings: a positive correlation between APOA1 and anti-tumor immune cells (NK, CD8<sup>+</sup> T cells) and a negative association with immune cells exerting immunosuppressive effects, including M2 macrophages.</p><p><strong>Conclusion: </strong>This is an integrative multidimensional exploration of APOA1 using bioinformatics and experiments. Both the prognostic value and anti-tumor effects based on APOA1 panoramic exploration in the HCC TME demonstrate a new potential clinical target for HCC assessment and intervention in the future.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence-based non-invasive tumor segmentation, grade stratification and prognosis prediction for clear-cell renal-cell carcinoma. 基于人工智能的透明细胞肾细胞癌无创肿瘤分割、分级分层及预后预测。
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-08-17 eCollection Date: 2023-09-01 DOI: 10.1093/pcmedi/pbad019
Siteng Chen, Dandan Song, Lei Chen, Tuanjie Guo, Beibei Jiang, Aie Liu, Xianpan Pan, Tao Wang, Heting Tang, Guihua Chen, Zhong Xue, Xiang Wang, Ning Zhang, Junhua Zheng
Abstract Due to the complicated histopathological characteristics of clear-cell renal-cell carcinoma (ccRCC), non-invasive prognosis before operative treatment is crucial in selecting the appropriate treatment. A total of 126 345 computerized tomography (CT) images from four independent patient cohorts were included for analysis in this study. We propose a V Bottleneck multi-resolution and focus-organ network (VB-MrFo-Net) using a cascade framework for deep learning analysis. The VB-MrFo-Net achieved better performance than VB-Net in tumor segmentation, with a Dice score of 0.87. The nuclear-grade prediction model performed best in the logistic regression classifier, with area under curve values from 0.782 to 0.746. Survival analysis revealed that our prediction model could significantly distinguish patients with high survival risk, with a hazard ratio (HR) of 2.49 [95% confidence interval (CI): 1.13–5.45, P = 0.023] in the General cohort. Excellent performance had also been verified in the Cancer Genome Atlas cohort, the Clinical Proteomic Tumor Analysis Consortium cohort, and the Kidney Tumor Segmentation Challenge cohort, with HRs of 2.77 (95%CI: 1.58–4.84, P = 0.0019), 3.83 (95%CI: 1.22–11.96, P = 0.029), and 2.80 (95%CI: 1.05–7.47, P = 0.025), respectively. In conclusion, we propose a novel VB-MrFo-Net for the renal tumor segmentation and automatic diagnosis of ccRCC. The risk stratification model could accurately distinguish patients with high tumor grade and high survival risk based on non-invasive CT images before surgical treatments, which could provide practical advice for deciding treatment options.
由于透明细胞肾细胞癌(clear-cell renal-cell carcinoma, ccRCC)复杂的组织病理特征,术前无创预后对选择合适的治疗方案至关重要。本研究共纳入来自4个独立患者队列的123445张计算机断层扫描(CT)图像进行分析。我们提出了一个使用级联框架进行深度学习分析的V瓶颈多分辨率和焦点器官网络(VB-MrFo-Net)。VB-MrFo-Net在肿瘤分割方面的表现优于VB-Net,其Dice评分为0.87。核级预测模型在logistic回归分类器中表现最好,曲线下面积在0.782 ~ 0.746之间。生存分析显示,我们的预测模型能够显著区分高生存风险患者,在普通队列中,风险比(HR)为2.49[95%置信区间(CI): 1.13-5.45, P = 0.023]。在Cancer Genome Atlas队列、Clinical Proteomic Tumor Analysis Consortium队列和Kidney Tumor Segmentation Challenge队列中,HRs分别为2.77 (95%CI: 1.58-4.84, P = 0.0019)、3.83 (95%CI: 1.22-11.96, P = 0.029)和2.80 (95%CI: 1.05-7.47, P = 0.025)。总之,我们提出了一种新的VB-MrFo-Net用于肾肿瘤的分割和ccRCC的自动诊断。该风险分层模型可根据术前无创CT图像准确区分肿瘤分级高、生存风险高的患者,为治疗方案的选择提供实用建议。
{"title":"Artificial intelligence-based non-invasive tumor segmentation, grade stratification and prognosis prediction for clear-cell renal-cell carcinoma.","authors":"Siteng Chen, Dandan Song, Lei Chen, Tuanjie Guo, Beibei Jiang, Aie Liu, Xianpan Pan, Tao Wang, Heting Tang, Guihua Chen, Zhong Xue, Xiang Wang, Ning Zhang, Junhua Zheng","doi":"10.1093/pcmedi/pbad019","DOIUrl":"10.1093/pcmedi/pbad019","url":null,"abstract":"Abstract Due to the complicated histopathological characteristics of clear-cell renal-cell carcinoma (ccRCC), non-invasive prognosis before operative treatment is crucial in selecting the appropriate treatment. A total of 126 345 computerized tomography (CT) images from four independent patient cohorts were included for analysis in this study. We propose a V Bottleneck multi-resolution and focus-organ network (VB-MrFo-Net) using a cascade framework for deep learning analysis. The VB-MrFo-Net achieved better performance than VB-Net in tumor segmentation, with a Dice score of 0.87. The nuclear-grade prediction model performed best in the logistic regression classifier, with area under curve values from 0.782 to 0.746. Survival analysis revealed that our prediction model could significantly distinguish patients with high survival risk, with a hazard ratio (HR) of 2.49 [95% confidence interval (CI): 1.13–5.45, P = 0.023] in the General cohort. Excellent performance had also been verified in the Cancer Genome Atlas cohort, the Clinical Proteomic Tumor Analysis Consortium cohort, and the Kidney Tumor Segmentation Challenge cohort, with HRs of 2.77 (95%CI: 1.58–4.84, P = 0.0019), 3.83 (95%CI: 1.22–11.96, P = 0.029), and 2.80 (95%CI: 1.05–7.47, P = 0.025), respectively. In conclusion, we propose a novel VB-MrFo-Net for the renal tumor segmentation and automatic diagnosis of ccRCC. The risk stratification model could accurately distinguish patients with high tumor grade and high survival risk based on non-invasive CT images before surgical treatments, which could provide practical advice for deciding treatment options.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76120002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in diagnosis and prediction for aggression of pure solid T1 lung cancer. 纯实体T1型肺癌侵袭性诊断与预测研究进展。
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-08-17 eCollection Date: 2023-09-01 DOI: 10.1093/pcmedi/pbad020
Junhao Mu, Jing Huang, Min Ao, Weiyi Li, Li Jiang, Li Yang

A growing number of early-stage lung cancers presenting as malignant pulmonary nodules have been diagnosed because of the increased adoption of low-dose spiral computed tomography. But pure solid T1 lung cancer with ≤3 cm in the greatest dimension is not always at an early stage, despite its small size. This type of cancer can be highly aggressive and is associated with pathological involvement, metastasis, postoperative relapse, and even death. However, it is easily misdiagnosed or delay diagnosed in clinics and thus poses a serious threat to human health. The percentage of nodal or extrathoracic metastases has been reported to be >20% in T1 lung cancer. As such, understanding and identifying the aggressive characteristics of pure solid T1 lung cancer is crucial for prevention, diagnosis, and therapeutic strategies, and beneficial to improving the prognosis. With the widespread of lung cancer screening, these highly invasive pure solid T1 lung cancer will become the main advanced lung cancer in future. However, there is limited information regarding precision medicine on how to identify these "early-stage" aggressive lung cancers. To provide clinicians with new insights into early recognition and intervention of the highly invasive pure solid T1 lung cancer, this review summarizes its clinical characteristics, imaging, pathology, gene alterations, immune microenvironment, multi-omics, and current techniques for diagnosis and prediction.

越来越多的早期肺癌表现为恶性肺结节已被诊断,因为越来越多的采用低剂量螺旋计算机断层扫描。但最大尺寸≤3cm的纯实体T1肺癌虽然体积小,但并不总是处于早期。这种类型的癌症具有很强的侵袭性,与病理累及、转移、术后复发甚至死亡有关。但在临床上极易误诊或延误诊断,对人体健康构成严重威胁。据报道,T1期肺癌的淋巴结或胸外转移率>20%。因此,了解和识别纯实体T1型肺癌的侵袭性特征对预防、诊断和治疗策略至关重要,有利于改善预后。随着肺癌筛查的广泛开展,这些高侵袭性纯实体T1型肺癌将成为未来晚期肺癌的主要类型。然而,关于如何识别这些“早期”侵袭性肺癌的精准医学信息有限。本文综述了高侵袭性纯实体T1肺癌的临床特点、影像学、病理、基因改变、免疫微环境、多组学以及目前的诊断和预测技术,为临床医生提供早期识别和干预提供新的见解。
{"title":"Advances in diagnosis and prediction for aggression of pure solid T1 lung cancer.","authors":"Junhao Mu, Jing Huang, Min Ao, Weiyi Li, Li Jiang, Li Yang","doi":"10.1093/pcmedi/pbad020","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad020","url":null,"abstract":"<p><p>A growing number of early-stage lung cancers presenting as malignant pulmonary nodules have been diagnosed because of the increased adoption of low-dose spiral computed tomography. But pure solid T1 lung cancer with ≤3 cm in the greatest dimension is not always at an early stage, despite its small size. This type of cancer can be highly aggressive and is associated with pathological involvement, metastasis, postoperative relapse, and even death. However, it is easily misdiagnosed or delay diagnosed in clinics and thus poses a serious threat to human health. The percentage of nodal or extrathoracic metastases has been reported to be >20% in T1 lung cancer. As such, understanding and identifying the aggressive characteristics of pure solid T1 lung cancer is crucial for prevention, diagnosis, and therapeutic strategies, and beneficial to improving the prognosis. With the widespread of lung cancer screening, these highly invasive pure solid T1 lung cancer will become the main advanced lung cancer in future. However, there is limited information regarding precision medicine on how to identify these \"early-stage\" aggressive lung cancers. To provide clinicians with new insights into early recognition and intervention of the highly invasive pure solid T1 lung cancer, this review summarizes its clinical characteristics, imaging, pathology, gene alterations, immune microenvironment, multi-omics, and current techniques for diagnosis and prediction.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The latest breakthrough on genetic characteristics of inflammatory bowel disease in Chinese and other East Asian ancestries. 中国和其他东亚祖先炎症性肠病遗传特征的最新突破。
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-08-01 DOI: 10.1093/pcmedi/pbad017
Han Gao, Zhanju Liu

Inflammatory bowel diseases (IBDs) are complex chronic disorders of the gastrointestinal tract with the following two subtypes: Crohn's disease and ulcerative colitis. Disease presentation and progression within and across IBDs, especially Crohn's disease, are highly heterogeneous in the location, severity of inflammation, intestinal stenosis and obstruction, and extraintestinal manifestations. Clinical classifications fail to accurately predict the disease course and response to therapies. To date, most IBD genetic associations are derived from individuals of European ancestries, leading to a limitation of the discovery and application of IBD genetics in the rest of the world populations. In this mini-review, we summarize the latest progress of genome-wide association studies of IBD across global ancestries especially the Chinese population, the similarities and differences in genetic architecture between European and East Asian ancestries, as well as, the clinical significances relevant to IBD genetic study.

炎症性肠病(IBDs)是胃肠道复杂的慢性疾病,有以下两种亚型:克罗恩病和溃疡性结肠炎。ibd内部和内部的疾病表现和进展,特别是克罗恩病,在部位、炎症的严重程度、肠狭窄和梗阻以及肠外表现方面高度不同。临床分类不能准确预测病程和对治疗的反应。迄今为止,大多数IBD遗传关联来自欧洲血统的个体,导致IBD遗传学在世界其他人群中的发现和应用受到限制。在这篇综述中,我们总结了IBD全基因组关联研究的最新进展,特别是中国人群,欧洲和东亚祖先遗传结构的异同,以及与IBD遗传研究相关的临床意义。
{"title":"The latest breakthrough on genetic characteristics of inflammatory bowel disease in Chinese and other East Asian ancestries.","authors":"Han Gao,&nbsp;Zhanju Liu","doi":"10.1093/pcmedi/pbad017","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad017","url":null,"abstract":"<p><p>Inflammatory bowel diseases (IBDs) are complex chronic disorders of the gastrointestinal tract with the following two subtypes: Crohn's disease and ulcerative colitis. Disease presentation and progression within and across IBDs, especially Crohn's disease, are highly heterogeneous in the location, severity of inflammation, intestinal stenosis and obstruction, and extraintestinal manifestations. Clinical classifications fail to accurately predict the disease course and response to therapies. To date, most IBD genetic associations are derived from individuals of European ancestries, leading to a limitation of the discovery and application of IBD genetics in the rest of the world populations. In this mini-review, we summarize the latest progress of genome-wide association studies of IBD across global ancestries especially the Chinese population, the similarities and differences in genetic architecture between European and East Asian ancestries, as well as, the clinical significances relevant to IBD genetic study.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/8d/pbad017.PMC10346401.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating biomarkers in perioperative management of cancer patients. 循环生物标志物在癌症患者围手术期管理中的应用。
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-06-30 eCollection Date: 2023-09-01 DOI: 10.1093/pcmedi/pbad018
Qiyuan Huang, Ruihao Zhou, Xuechao Hao, Weiyi Zhang, Guo Chen, Tao Zhu

Owing to the advances in surgical technology, most solid tumours can be controlled by surgical excision. The priority should be tumour control, while some routine perioperative management might influence cancer progression in an unnoticed way. Moreover, it is increasingly recognized that effective perioperative management should include techniques to improve postoperative outcomes. These influences are elucidated by the different functions of circulating biomarkers in cancer patients. Here, circulating biomarkers with two types of clinical functions were reviewed: (i) circulating biomarkers for cancer progression monitoring, for instance, those related to cancer cell malignancy, tumour microenvironment formation, and early metastasis, and (ii) circulating biomarkers with relevance to postoperative outcomes, including systemic inflammation, immunosuppression, cognitive dysfunction, and pain management. This review aimed to provide new perspectives for the perioperative management of patients with cancer and highlight the potential clinical translation value of circulating biomarkers in improving outcomes.

由于外科技术的进步,大多数实体瘤可以通过手术切除来控制。应优先考虑肿瘤控制,而一些常规围手术期管理可能会以不被注意的方式影响癌症的进展。此外,人们越来越认识到有效的围手术期管理应包括改善术后预后的技术。这些影响是通过癌症患者循环生物标志物的不同功能来阐明的。本文综述了具有两种临床功能的循环生物标志物:(i)用于癌症进展监测的循环生物标志物,例如与癌细胞恶性、肿瘤微环境形成和早期转移相关的循环生物标志物;(ii)与术后预后相关的循环生物标志物,包括全身炎症、免疫抑制、认知功能障碍和疼痛管理。本综述旨在为癌症患者围手术期管理提供新的视角,并强调循环生物标志物在改善预后方面的潜在临床转化价值。
{"title":"Circulating biomarkers in perioperative management of cancer patients.","authors":"Qiyuan Huang, Ruihao Zhou, Xuechao Hao, Weiyi Zhang, Guo Chen, Tao Zhu","doi":"10.1093/pcmedi/pbad018","DOIUrl":"10.1093/pcmedi/pbad018","url":null,"abstract":"<p><p>Owing to the advances in surgical technology, most solid tumours can be controlled by surgical excision. The priority should be tumour control, while some routine perioperative management might influence cancer progression in an unnoticed way. Moreover, it is increasingly recognized that effective perioperative management should include techniques to improve postoperative outcomes. These influences are elucidated by the different functions of circulating biomarkers in cancer patients. Here, circulating biomarkers with two types of clinical functions were reviewed: (i) circulating biomarkers for cancer progression monitoring, for instance, those related to cancer cell malignancy, tumour microenvironment formation, and early metastasis, and (ii) circulating biomarkers with relevance to postoperative outcomes, including systemic inflammation, immunosuppression, cognitive dysfunction, and pain management. This review aimed to provide new perspectives for the perioperative management of patients with cancer and highlight the potential clinical translation value of circulating biomarkers in improving outcomes.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78263519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction of regulatory network for alopecia areata progression and identification of immune monitoring genes based on multiple machine-learning algorithms. 基于多机器学习算法的斑秃进展调控网络构建及免疫监测基因鉴定。
IF 5.3 4区 医学 Q1 Medicine Pub Date : 2023-06-01 DOI: 10.1093/pcmedi/pbad009
Jiachao Xiong, Guodong Chen, Zhixiao Liu, Xuemei Wu, Sha Xu, Jun Xiong, Shizhao Ji, Minjuan Wu

Objectives: Alopecia areata (AA) is an autoimmune-related non-cicatricial alopecia, with complete alopecia (AT) or generalized alopecia (AU) as severe forms of AA. However, there are limitations in early identification of AA, and intervention of AA patients who may progress to severe AA will help to improve the incidence rate and prognosis of severe AA.

Methods: We obtained two AA-related datasets from the gene expression omnibus database, identified the differentially expressed genes (DEGs), and identified the module genes most related to severe AA through weighted gene co-expression network analysis. Functional enrichment analysis, construction of a protein-protein interaction network and competing endogenous RNA network, and immune cell infiltration analysis were performed to clarify the underlying biological mechanisms of severe AA. Subsequently, pivotal immune monitoring genes (IMGs) were screened through multiple machine-learning algorithms, and the diagnostic effectiveness of the pivotal IMGs was validated by receiver operating characteristic.

Results: A total of 150 severe AA-related DEGs were identified; the upregulated DEGs were mainly enriched in immune response, while the downregulated DEGs were mainly enriched in pathways related to hair cycle and skin development. Four IMGs (LGR5, SHISA2, HOXC13, and S100A3) with good diagnostic efficiency were obtained. As an important gene of hair follicle stem cells stemness, we verified in vivo that LGR5 downregulation may be an important link leading to severe AA.

Conclusion: Our findings provide a comprehensive understanding of the pathogenesis and underlying biological processes in patients with AA, and identification of four potential IMGs, which is helpful for the early diagnosis of severe AA.

目的:斑秃(Alopecia areata, AA)是一种自身免疫性非瘢痕性脱发,完全性脱发(complete Alopecia, AT)或全身性脱发(generalized Alopecia, AU)是斑秃的严重形式。然而,早期识别AA存在局限性,对可能发展为重度AA的AA患者进行干预将有助于改善重度AA的发病率和预后。方法:从基因表达综合数据库中获取两组AA相关数据集,鉴定差异表达基因(differential expression genes, DEGs),并通过加权基因共表达网络分析,鉴定与重度AA最相关的模块基因。通过功能富集分析、蛋白质相互作用网络和竞争内源RNA网络的构建以及免疫细胞浸润分析,阐明严重AA的潜在生物学机制。随后,通过多种机器学习算法筛选关键免疫监测基因(IMGs),并通过受试者操作特征验证关键免疫监测基因的诊断有效性。结果:共鉴定出150例严重aa相关deg;上调的DEGs主要富集于免疫应答,下调的DEGs主要富集于与毛发周期和皮肤发育相关的通路。获得了诊断效能较好的4个img (LGR5、SHISA2、HOXC13、S100A3)。作为毛囊干细胞干性的重要基因,我们在体内证实LGR5下调可能是导致严重AA的重要环节。结论:我们的研究结果为AA患者的发病机制和潜在的生物学过程提供了全面的认识,并确定了4种潜在的IMGs,有助于早期诊断重度AA。
{"title":"Construction of regulatory network for alopecia areata progression and identification of immune monitoring genes based on multiple machine-learning algorithms.","authors":"Jiachao Xiong,&nbsp;Guodong Chen,&nbsp;Zhixiao Liu,&nbsp;Xuemei Wu,&nbsp;Sha Xu,&nbsp;Jun Xiong,&nbsp;Shizhao Ji,&nbsp;Minjuan Wu","doi":"10.1093/pcmedi/pbad009","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad009","url":null,"abstract":"<p><strong>Objectives: </strong>Alopecia areata (AA) is an autoimmune-related non-cicatricial alopecia, with complete alopecia (AT) or generalized alopecia (AU) as severe forms of AA. However, there are limitations in early identification of AA, and intervention of AA patients who may progress to severe AA will help to improve the incidence rate and prognosis of severe AA.</p><p><strong>Methods: </strong>We obtained two AA-related datasets from the gene expression omnibus database, identified the differentially expressed genes (DEGs), and identified the module genes most related to severe AA through weighted gene co-expression network analysis. Functional enrichment analysis, construction of a protein-protein interaction network and competing endogenous RNA network, and immune cell infiltration analysis were performed to clarify the underlying biological mechanisms of severe AA. Subsequently, pivotal immune monitoring genes (IMGs) were screened through multiple machine-learning algorithms, and the diagnostic effectiveness of the pivotal IMGs was validated by receiver operating characteristic.</p><p><strong>Results: </strong>A total of 150 severe AA-related DEGs were identified; the upregulated DEGs were mainly enriched in immune response, while the downregulated DEGs were mainly enriched in pathways related to hair cycle and skin development. Four IMGs (LGR5, SHISA2, HOXC13, and S100A3) with good diagnostic efficiency were obtained. As an important gene of hair follicle stem cells stemness, we verified <i>in vivo</i> that LGR5 downregulation may be an important link leading to severe AA.</p><p><strong>Conclusion: </strong>Our findings provide a comprehensive understanding of the pathogenesis and underlying biological processes in patients with AA, and identification of four potential IMGs, which is helpful for the early diagnosis of severe AA.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/f9/pbad009.PMC10268596.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9716786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Precision Clinical Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1